Bridget Stuart1, Jenny H Lin, Peter J Mogayzel. 1. Eudowood Division of Pediatric Respiratory Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287-2533, USA.
Abstract
Pseudomonas aeruginosa (Pa) is the predominant organism infecting the airways of patients with cystic fibrosis (CF). This organism has an armamentarium of survival mechanisms that allows it to survive in the CF airway. Since colonization and chronic infection with Pa is associated with poorer lung function and increased morbidity and mortality, therapies that can prevent infection could significantly improve the lives of patients with CF. Numerous studies have examined the effects of treatment on the eradication of Pa as a means to ameliorate disease. This article outlines the pathophysiology and clinical implication of Pa acquisition, and reviews the existing treatment regimens aimed at early eradication of Pa in patients with CF. Copyright 2010 Elsevier Ltd. All rights reserved.
pan class="Species">Pseudomonas aeruginosa (pan class="Species">Pa) is the predominant organism infecting the airways of pan class="Species">patients with cystic fibrosis (CF). This organism has an armamentarium of survival mechanisms that allows it to survive in the CF airway. Since colonization and chronic infection with Pa is associated with poorer lung function and increased morbidity and mortality, therapies that can prevent infection could significantly improve the lives of patients with CF. Numerous studies have examined the effects of treatment on the eradication of Pa as a means to ameliorate disease. This article outlines the pathophysiology and clinical implication of Pa acquisition, and reviews the existing treatment regimens aimed at early eradication of Pa in patients with CF. Copyright 2010 Elsevier Ltd. All rights reserved.
Authors: Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson Journal: J Pediatr Date: 2007-06-22 Impact factor: 4.406
Authors: Miriam M Treggiari; Margaret Rosenfeld; Nicole Mayer-Hamblett; George Retsch-Bogart; Ronald L Gibson; Judy Williams; Julia Emerson; Richard A Kronmal; Bonnie W Ramsey Journal: Contemp Clin Trials Date: 2009-01-15 Impact factor: 2.226
Authors: Jodi E Gustave; Joseph A Jurcisek; Karen S McCoy; Steven D Goodman; Lauren O Bakaletz Journal: J Cyst Fibros Date: 2012-11-17 Impact factor: 5.482
Authors: Hengameh H Raissy; Graham Timmins; Lea Davies; Theresa Heynekamp; Michelle Harkins; Zachary D Sharp; H William Kelly Journal: Pediatr Allergy Immunol Pulmonol Date: 2016-06-01 Impact factor: 1.349